The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial

Title
The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial
Author(s)
박종선조영락[조영락]김영대[김영대]박태호[박태호]박경일[박경일]박종성[박종성]백희경[백희경]최선영[최선영]김기식[김기식]홍택종[홍택종]양태현[양태현]황진용[황진용]허승호[허승호]이상곤[이상곤]
Keywords
ACUTE MYOCARDIAL-INFARCTION; CHRONIC HEART-FAILURE; CONVERTING-ENZYME-INHIBITOR; DYSFUNCTION; MORBIDITY; MORTALITY; CAPTOPRIL; SIZE; LISINOPRIL; ENALAPRIL
Issue Date
201111
Publisher
BIOMED CENTRAL LTD
Citation
TRIALS, v.12
Abstract
Background: Angiotensin-converting enzyme inhibitors and the angiotensin-receptor blocker valsartan ameliorate ventricular remodeling after myocardial infarction (MI). Based on previous clinical trials, a maximum clinical dose is recommended in practical guidelines. Yet, has not been clearly demonstrated whether the recommended dose is more efficacious compared to the lower dose that is commonly used in clinical practice. Method/Design: Valsartan in post-MI remodeling (VALID) is a randomized, open-label, single-blinded multicenter study designed to compare the efficacy of different clinical dose of valsartan on the post-MI ventricular remodeling. This study also aims to assess neurohormone change and clinical parameters of patients during the post-infarct period. A total of 1116 patients with left ventricular dysfunction following the first episode of acute ST-elevation MI are to be enrolled and randomized to a maximal tolerable dose (up to 320 mg/day) or usual dose (80 mg/day) of valsartan for 12 months in 2: 1 ratio. Echocardiographic analysis for quantifying post-MI ventricular remodeling is to be conducted in central core laboratory. Clinical assessment and laboratory test are performed at fixed times. Discussion: VALID is a multicenter collaborative study to evaluate the impact of dose of valsartan on the post-MI ventricular remodeling. The results of the study provide information about optimal dosing of the drug in the management of patients after MI. The results will be available by 2012.
URI
http://hdl.handle.net/YU.REPOSITORY/24299http://dx.doi.org/10.1186/1745-6215-12-247
ISSN
1745-6215
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE